A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus

Trial Profile

A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Dulaglutide (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Feb 2018 Results of post hoc subgroup analysis assessing dulaglutide efficacy by baseline beta cell function (low, medium, and high values of fasting C-peptide, C-peptide index, and secretory units of islets in transplantation (SUIT) index) in Japanese patients published in the Diabetes Therapy
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2015 Results published in an Eli Lilly Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top